Categories Earnings, Technology

Autodesk once again guides below expectation

Autodesk (NASDAQ: ADSK) said its revenue for the third quarter surged 28% to $843 million due to strong performance from all of its products. Adjusted earnings jumped to 78 cents compared to 29 cents reported last year. The Q3 headline numbers came ahead of market estimates.

Annualized recurring revenue (ARR) rose 2%, billings jumped 55% and deferred revenue recorded a 35% jump over the prior year. The revenue retention rate was healthier between 110-120%. 

Autodesk Q3 2019 earnings infographic

Weak Outlook 

However, once again Autodesk disappointed in terms of guidance. For the Q4 period, Autodesk is expecting revenue in the range of $880 million – $895 million and adjusted EPS of 86 to 91 cents. The fell shy of what the street was anticipating.

For the full year, the company projected a 27% jump in revenues to a range of $3.25 billion to $3.27 billion. Adjusted EPS is forecast between $2.74 and $2.79.

The weak guidance sent the stock tanking 5.4% during after market hours on Thursday.

Autodesk decided to transition from a licensing-based business model towards a software-as-a-service model in 2016. As a follow-up to the transition, the company launched maintenance-to-subscription (M2S) program in 2017, which helps its existing clients to convert from the licensing model to SaaS plan.

In the past two years, the company has converted 875,000 customers to SaaS offering and plans to move the remaining 689,000 in the near future.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top